Pluristem Therapeutics Inc. announced that its wholly owned subsidiary, Pluristem Ltd., has been awarded 12.7 million New Israeli Shekels (approximately $3.3 million) from the Israel Innovation Authority (previously the Office of the Chief Scientist) of the Israeli Ministry of Economy & Industry.
The grant will support clinical trials and R&D activities for calendar year 2016.
“We are delighted to receive the Israeli Innovation Authority Grant this year,” said Zami Aberman, Chairman and CEO. “The continued backing of the Israeli Innovation Authority is a vote of confidence in Pluristem technology and strategy and support the execution of our plans.”
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!